For semaglutide, median weight loss increased from approximately 56% at 1.0 mg to around 10% at 2.4 mg, with further reductions observed at 7.2 mg
Common problems include: Incomplete paperwork: missing fields, unsigned forms, or omitted chart attachments Weak evidence of medical necessity: the diagnosis is present, but the supporting history is thin Missing comorbidity documentation: the condition may be in the patients history but not clearly included in the submission No proof of prior lifestyle effort: many plans want evidence, not just a statement Step therapy gaps: if the plan requires trying another option first, that requirement has to be addressed directly Some patients also run into a coverage issue that has nothing to do with their health
Decreased glucagon-like peptide 1 receptor expression in endothelial and smooth muscle cells in diabetic db/db mice: TCF7L2 is a possible regulator of the vascular glucagon-like peptide 1 receptor
This can be achieved by crossing the blood-brain-barrier involving saturable mechanisms (Banks et al., 2002), by diffusing through fenestrated capillaries at circumventricular organs (Uriarte et al., 2021), or by crossing the blood-cerebrospinal barrier (Uriarte et al., 2019)